![]() | Up a level |
Saw, Stephanie P. L. and Zhong, Wen-Zhao and Fu, Rui and Li, Molly S. C. and Goto, Yasushi and Fox, Stephen B. and Yatabe, Yasushi and Ong, Boon-Hean and Ng, Calvin S. H. and Lee, David D. W. and Phuong, Pham Cam and Park, In Kyu and Yang, James C. H. and Tsuboi, Masahiro and Tho, Lye Mun and John, Thomas and Hsu, Hsao-Hsun and Tan, Daniel S. W. and Mok, Tony S. K. and Reungwetwattana, Thanyanan and Singh, Navneet (2025) Asian Thoracic Oncology Research Group expert consensus statement on the peri-operative management of non-small cell lung cancer. Lung Cancer, 200. p. 108076. ISSN 0169-5002, DOI https://doi.org/10.1016/j.lungcan.2024.108076.
Wu, Yi-Long and Guarneri, Valentina and Voon, Pei Jye and Lim, Boon Khaw and Yang, Jin-Ji and Wislez, Marie and Huang, Cheng and Liam, Chong Kin and Mazieres, Julien and Tho, Lye Mun and Hayashi, Hidetoshi and Nhung, Nguyen Viet and Chia, Puey Ling and de Marinis, Filippo and Raskin, Jo and Zhou, Qinghua and Finocchiaro, Giovanna and Le, Anh Tuan and Wang, Jialei and Dooms, Christophe and Kato, Terufumi and Nadal, Ernest and Hin, How Soon and Smit, Egbert F. and Wermke, Martin and Tan, Daniel and Morise, Masahiro and O'Brate, Aurora and Adrian, Svenja and Pfeiffer, Boris M. and Stroh, Christopher and Juraeva, Dilafruz and Strotmann, Rainer and Goteti, Kosalaram and Berghoff, Karin and Ellers-Lenz, Barbara and Karachaliou, Niki and Le, Xiuning and Kim, Tae Min and INSIGHT investigators, - (2024) Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial. Lancet Oncology, 25 (8). pp. 989-1002. ISSN 1470-2045, DOI https://doi.org/10.1016/S1470-2045(24)00270-5.
Poh, Mau Ern and Balakrishnan, Sivasubramaniam and Tan, Sin Nee and Abidin, Muhammad Adil Zainal and Liam, Chong Kin and Tan, Jiunn Liang and Pang, Yong Kek and Alaga, Arvindran and Tho, Lye Mun and How, Soon Hin (2024) Real-world efficacy of low dose osimertinib as second-line treatment in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer. Translational Lung Cancer Research, 13 (7). pp. 1649-1659. ISSN 2218-6751, DOI https://doi.org/10.21037/tlcr-24-243.
Poh, Mau Ern and Chai, Chee Shee and Liam, Chong Kin and Ho, Gwo Fuang and Pang, Yong Kek and Hasbullah, Harissa Husainy and Tho, Lye Mun and Nor, Ibtisam Muhamad and Ho, Kean Fatt and Thiagarajan, Muthukkumaran and Samsudin, Azlina and Omar, Azza and Ong, Choo Khoon and Soon, Sing Yang and Tan, Sin Nee and How, Soon Hin (2024) Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small cell lung cancer in real-world clinical practice? Translational Lung Cancer Research, 13 (2). pp. 307-320. ISSN 2218-6751, DOI https://doi.org/10.21037/tlcr-23-691.
Poh, Mau Ern and How, Soon Hin and Ho, Gwo Fuang and Pang, Yong Kek and Hasbullah, Harissa H. and Tho, Lye Mun and Nor, Ibtisam Muhamad and Lim, Bee Chiu and Ho, Kean Fatt and Thiagarajan, Muthukkumaran and Samsudin, Azlina and Omar, Azza and Ong, Choo Khoon and Soon, Sing Yang and Tan, Justin Yu Kuan and Abidin, Muhammad Adil Zainal (2023) Real-world treatment and outcomes of ALK-positive metastatic non-small cell lung cancer in a Southeast Asian country. Cancer Management And Research, 15. pp. 31-41. ISSN 1179-1322, DOI https://doi.org/10.2147/CMAR.S393729.
How, Soon Hin and Tho, Lye Mun and Liam, Chong Kin and Hasbullah, Harissa H. and Ho, Gwo Fuang and Nor, Ibtisam Muhammad and Poh, Mau Ern and Ho, Kean Fatt and Thiagarajan, Muthukkumaran and Samsudin, Azlina and Omar, Azza and Ong, Choo Khoon and Pang, Yong Kek and Soon, Sing Yang (2022) Programmed death-ligand 1 expression and use of immune checkpoint inhibitors among patients with advanced non-small-cell lung cancer in a resource-limited country. Thoracic Cancer, 13 (11). pp. 1676-1683. ISSN 1759-7706, DOI https://doi.org/10.1111/1759-7714.14442.
How, Soon Hin and Liam, Chong Kin and Abidin, Muhammad Adil Zainal and Hasbullah, Harissa H. and Tho, Lye Mun and Ho, Gwo Fuang and Nor, Ibtisam Muhamad and Pang, Yong Kek and Ho, Kean Fatt and Thiagarajan, Muthukkumaran and Ariffin, Roziana and Samsudin, Azlina and Omar, Azza and Tan, Sin Nee and Ong, Choo Khoon and Soon, Sing Yang and Poh, Mau Ern (2022) Outcomes of patients with EGFR-mutant advanced NSCLC in a developing country in Southeast Asia. Cancer Management And Research, 14. pp. 1995-2005. ISSN 1179-1322, DOI https://doi.org/10.2147/CMAR.S364713.
Tan, Wan Ling and Chua, Kevin L. M. and Lin, Chia-Chi and Lee, Victor H. F. and Tho, Lye Mun and Chan, Anthony W. and Ho, Gwo Fuang and Reungwetwattana, Thanyanan and Yang, James C. and Kim, Dong-Wan and Soo, Ross A. and Ahn, Yong Chan and Onishi, Hiroshi and Ahn, Myung-Ju and Mok, Tony S. K. and Tan, Daniel S. W. and Yang, Fan (2020) Asian thoracic oncology research group expert consensus statement on optimal management of stage III NSCLC. Journal of Thoracic Oncology, 15 (3). pp. 324-343. ISSN 1556-0864, DOI https://doi.org/10.1016/j.jtho.2019.10.022.